person · Reporting owner

Sirgo Mark A

Disclosed activity across 3 companies

Tapewire entity: 114901
SEC CIK: 0001301715

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
9 METERS BIOPHARMA, INC.NMTR · Entity 114271	Director	March 29, 2023	March 31, 2023
BIOMERICA INCBMRA · Entity 8171	Director	December 09, 2021	December 10, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

9 METERS BIOPHARMA, INC.

Report date March 29, 2023 · Filed March 31, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	85,907	Reported balance After 2023-03-29 transaction · row 1 1 source row Row 1 · 2023-03-29 · Grant · Acquired 7,885 · Balance 85,907 F1: Represents Restricted Stock Units ("RSUs") granted pursuant to the 9 Meters Biopharma, Inc. 2022 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting date. The RSUs vest as follows: 3,943 shares vest on April 15, 2023 and 3,942 shares vest on December 31, 2023. The vesting of the December 31, 2023 RSUs will accelerate upon a Change in Control prior to December 31, 2023.
Common StockSEC Table I · non-derivative	IndirectBy spouse	1,075	Reported balance Holding disclosure · report date 2023-03-29 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,075

Filing footnotes · ownership attribution and instrument terms

F1: Represents Restricted Stock Units ("RSUs") granted pursuant to the 9 Meters Biopharma, Inc. 2022 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting date. The RSUs vest as follows: 3,943 shares vest on April 15, 2023 and 3,942 shares vest on December 31, 2023. The vesting of the December 31, 2023 RSUs will accelerate upon a Change in Control prior to December 31, 2023.

BIOMERICA INC

Report date December 09, 2021 · Filed December 10, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Non-qualified stock optionSEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2031-12-09	Direct	170,000	Reported balance After 2021-12-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-12-09 · Grant · Acquired 25,000 · Balance 170,000 F1: Not applicable
Common stockSEC Table I · non-derivative	Direct	8,700	Reported balance Holding disclosure · report date 2021-12-09 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 8,700

Filing footnotes · ownership attribution and instrument terms

F1: Not applicable

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

BIODELIVERY SCIENCES INTERNATIONAL INC

Report date March 22, 2022 · Filed March 22, 2022

Section 16 reporting ended · disclosed 2022-03-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-03-22 transaction · row 1 1 source row Row 1 · 2022-03-22 · Other · Disposed 1,166,866 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2022-03-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-03-22 · Disposition to issuer · Disposed 11,685 · Balance 0 F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F3: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.96	Direct	Reported balance After 2022-03-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-03-22 · Disposition to issuer · Disposed 22,500 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36	Direct	Reported balance After 2022-03-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-03-22 · Disposition to issuer · Disposed 48,000 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.76	Direct	Reported balance After 2022-03-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-03-22 · Disposition to issuer · Disposed 48,000 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66	Direct	Reported balance After 2022-03-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-03-22 · Disposition to issuer · Disposed 85,760 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.

F3: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.

F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 30, 2020 Filed Jul 2, 2020 16:23 UTC	9 METERS BIOPHARMA, INC. NMTR · Entity 114271	ConversionSeries A Convertible Preferred Stock · Derivative	2,544	$0.00	$0.00	Disclosure SEC source: 0001551986-20-000204 · wf-form4_159372139303329.xml · derivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 254,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Convertible Preferred Stock automatically converted to common stock on a 1-to-100 basis upon approval by the Company's stockholders on June 30, 2020. F1 · derivative.expiration_date: The Series A Convertible Preferred Stock automatically converted to common stock on a 1-to-100 basis upon approval by the Company's stockholders on June 30, 2020. Read SEC document
June 30, 2020 Filed Jul 2, 2020 16:23 UTC	9 METERS BIOPHARMA, INC. NMTR · Entity 114271	ConversionCommon stock	254,400	$0.00	$0.00	Disclosure SEC source: 0001551986-20-000204 · wf-form4_159372139303329.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 15, 2020 Filed Jun 16, 2020 16:05 UTC	9 METERS BIOPHARMA, INC. NMTR · Entity 114271	PurchaseCommon stock	17,943	$0.60	$10,720.94	Disclosure SEC source: 0001551986-20-000174 · wf-form4_159233791299921.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,384 F1 · price: The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions ranging from $0.5925 and $0.60, inclusive. The reporting person undertakes to provide to 9 Meters Biopharma, Inc., any security holder of 9 Meters Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1 to this Form 4. Read SEC document
May 11, 2020 Filed May 12, 2020 18:48 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionRestricted Stock Units · Derivative	22,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001103021-20-000081 · wf-form4_158932369364623.xml · derivative · entry 3 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. F3 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. Read SEC document
May 11, 2020 Filed May 12, 2020 18:48 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionCommon Stock	22,500	$0.00	$0.00	Disclosure SEC source: 0001103021-20-000081 · wf-form4_158932369364623.xml · nonDerivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,287,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. Read SEC document
May 08, 2020 Filed May 12, 2020 18:48 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	100,000	$5.07	$507,000.00	Disclosure SEC source: 0001103021-20-000081 · wf-form4_158932369364623.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,264,595 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On May 8, 2020, the Reporting Person sold an aggregate of 100,000 shares of the Issuer's Common Stock at a weighted average price of $5.07 per share. The highest sale price for the Common Stock was $5.29 per share and the lowest sale price was $5.00 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document
May 04, 2020 Filed May 4, 2020 19:19 UTC	9 METERS BIOPHARMA, INC. NMTR · Entity 114271	PurchaseSeries A Convertible Preferred Warrant · Derivative	2,544	Not disclosed	Not disclosed	Disclosure SEC source: 0001551986-20-000126 · wf-form4_158863436611737.xml · derivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,400 Underlying: Common stock · 254,400 shares Expires 2025-05-04 F2 · derivative.exercise_price: The purchase price of the warrant was included with the purchase price of the Series A Convertible Preferred Stock. The Series A Preferred Warrant is convertible into Series A Preferred Stock on a 1-for-1 basis. F2 · price: The purchase price of the warrant was included with the purchase price of the Series A Convertible Preferred Stock. The Series A Preferred Warrant is convertible into Series A Preferred Stock on a 1-for-1 basis. Read SEC document
May 04, 2020 Filed May 4, 2020 19:19 UTC	9 METERS BIOPHARMA, INC. NMTR · Entity 114271	PurchaseSeries A Convertible Preferred Stock · Derivative	2,544	$0.00	$0.00	Disclosure SEC source: 0001551986-20-000126 · wf-form4_158863436611737.xml · derivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,400 Underlying: Common stock · 254,400 shares Expires not disclosed F1 · derivative.exercise_price: The purchase price of the Series A Convertible Preferred Stock was $58.94 per share. The Series A Preferred Stock is convertible into Common Stock upon stockholder approval on a 1-for-100 basis, with no expiration date. F1 · derivative.expiration_date: The purchase price of the Series A Convertible Preferred Stock was $58.94 per share. The Series A Preferred Stock is convertible into Common Stock upon stockholder approval on a 1-for-100 basis, with no expiration date. Read SEC document
April 30, 2020 Filed May 4, 2020 19:18 UTC	9 METERS BIOPHARMA, INC. NMTR · Entity 114271	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $0.70	$0.00	Disclosure SEC source: 0001551986-20-000125 · wf-form4_158863430740168.xml · derivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common stock · 50,000 shares Expires 2030-04-30 F1 · derivative.exercise_date: The option shall vest in 36 equal monthly installments beginning April 30, 2020. Read SEC document
April 27, 2020 Filed Apr 29, 2020 16:10 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	100,000	$4.58	$458,000.00	Disclosure SEC source: 0001103021-20-000060 · wf-form4_158819102893177.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,364,595 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On April 27, 2020, the Reporting Person sold an aggregate of 100,000 shares of the Issuer's Common Stock at a weighted average price of $4.58 per share. The highest sale price for the Common Stock was $4.63 per share and the lowest sale price was $4.50 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document
April 21, 2020 Filed Apr 21, 2020 20:57 UTC	BIOMERICA INC BMRA · Entity 8171	SaleCommon Stock	5,000	$8.11	$40,531.50	Disclosure SEC source: 0001513162-20-000089 · primary_doc.xml · nonDerivative · entry 7 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,700 Read SEC document
April 17, 2020 Filed Apr 21, 2020 20:57 UTC	BIOMERICA INC BMRA · Entity 8171	SaleCommon Stock	2,454	$8.08	$19,820.96	Disclosure SEC source: 0001513162-20-000089 · primary_doc.xml · nonDerivative · entry 6 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 Read SEC document
April 17, 2020 Filed Apr 21, 2020 20:57 UTC	BIOMERICA INC BMRA · Entity 8171	SaleCommon Stock	1,302	$8.07	$10,507.14	Disclosure SEC source: 0001513162-20-000089 · primary_doc.xml · nonDerivative · entry 5 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,154 Read SEC document
April 17, 2020 Filed Apr 21, 2020 20:57 UTC	BIOMERICA INC BMRA · Entity 8171	SaleCommon Stock	1,076	$8.05	$8,661.80	Disclosure SEC source: 0001513162-20-000089 · primary_doc.xml · nonDerivative · entry 4 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,456 Read SEC document
April 17, 2020 Filed Apr 21, 2020 20:57 UTC	BIOMERICA INC BMRA · Entity 8171	SaleCommon Stock	100	$8.06	$806.00	Disclosure SEC source: 0001513162-20-000089 · primary_doc.xml · nonDerivative · entry 3 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,532 Read SEC document
April 17, 2020 Filed Apr 21, 2020 20:57 UTC	BIOMERICA INC BMRA · Entity 8171	SaleCommon Stock	68	$8.09	$550.12	Disclosure SEC source: 0001513162-20-000089 · primary_doc.xml · nonDerivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,632 Read SEC document
April 15, 2020 Filed Apr 17, 2020 16:05 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	50,000	$4.13	$206,500.00	Disclosure SEC source: 0001103021-20-000056 · wf-form4_158715389257065.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,464,595 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On April 15, 2020, the Reporting Person sold an aggregate of 50,000 shares of the Issuer's Common Stock at a weighted average price of $4.13 per share. The highest sale price for the Common Stock was $4.22 per share and the lowest sale price was $4.03 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document
March 16, 2020 Filed Mar 18, 2020 16:17 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	GrantCommon Stock	36,471	$0.00	$0.00	Disclosure SEC source: 0001103021-20-000051 · wf-form4_158456263865709.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,514,595 F1 · kind: The shares of Common Stock were acquired by the Reporting Person as a result of the vesting of 36,471 Restricted Stock Units (RSUs) granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. Read SEC document
January 07, 2020 Filed Jan 9, 2020 16:03 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	13,353	$5.65	$75,444.45	Disclosure SEC source: 0001103021-20-000006 · wf-form4_157860379285944.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,478,124 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On January 7, 2020, the Reporting Person sold an aggregate of 13,353 shares of the Issuer's Common Stock at a weighted average price of $5.65 per share. The highest sale price for the Common Stock was $5.80 per share and the lowest sale price was $5.56 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document
January 06, 2020 Filed Jan 6, 2020 20:48 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	18,600	$5.84	$108,624.00	Disclosure SEC source: 0001103021-20-000004 · wf-form4_157836170766366.xml · nonDerivative · entry 3 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,491,477 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F3 · price: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F5 · price: On January 6, 2020 the Reporting Person sold an aggregate of 18,600 shares of the Issuer's Common Stock at a weighted average price of $5.84 per share. The highest sale price for the Common Stock was $5.92 per share and the lowest sale price was $5.75 per share. Read SEC document
January 03, 2020 Filed Jan 6, 2020 20:48 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	13,857	$6.00	$83,142.00	Disclosure SEC source: 0001103021-20-000004 · wf-form4_157836170766366.xml · nonDerivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,510,077 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F3 · price: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F4 · price: On January 3, 2020, the Reporting Person sold an aggregate of 13,857 shares of the Issuer's Common Stock at a weighted average price of $6.00 per share. The highest sale price for the Common Stock was $6.13 per share and the lowest sale price was $5.88 per share. Read SEC document
January 02, 2020 Filed Jan 6, 2020 20:48 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	54,190	$6.09	$330,017.10	Disclosure SEC source: 0001103021-20-000004 · wf-form4_157836170766366.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,523,934 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On January 2, 2020, the Reporting Person sold an aggregate of 54,190 shares of the Issuer's Common Stock at a weighted average price of $6.09 per share. The highest sale price for the Common Stock was $6.36 per share and the lowest sale price was $5.86 per share. F3 · price: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document
December 19, 2019 Filed Dec 23, 2019 21:55 UTC	BIOMERICA INC BMRA · Entity 8171	GrantNon Qualified Stock Option · Derivative	30,000	Not disclosed Strike: $2.81	Not disclosed	Disclosure SEC source: 0001513162-19-000260 · primary_doc.xml · derivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 30,000 shares Expires 2029-12-20 F1 · price: N/A Read SEC document
October 18, 2019 Filed Oct 22, 2019 16:36 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	84,228	$5.15	$433,774.20	Disclosure SEC source: 0001103021-19-000023 · wf-form4_157177654771191.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,578,124 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On October 18, 2019, the Reporting Person sold an aggregate of 84,228 shares of the Issuer's Common Stock at a weighted average price of $5.15 per share. The highest sale price for the Common Stock was $5.16 per share and the lowest sale price was $5.15 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document
October 17, 2019 Filed Oct 17, 2019 17:32 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	31,860	$5.15	$164,079.00	Disclosure SEC source: 0001103021-19-000021 · wf-form4_157134795109990.xml · nonDerivative · entry 3 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,662,352 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F4 · price: On October 17, 2019, the Reporting Person sold an aggregate of 31,860 shares of the Issuer's Common Stock at a weighted average price of $5.15 per share. The highest sale price for the Common Stock was $5.17 per share and the lowest sale price was $5.15 per share. Read SEC document
October 16, 2019 Filed Oct 17, 2019 17:32 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	8,912	$5.15	$45,896.80	Disclosure SEC source: 0001103021-19-000021 · wf-form4_157134795109990.xml · nonDerivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,694,212 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F3 · price: On October 16, 2019, the Reporting Person sold an aggregate of 8,912 shares of the Issuer's Common Stock at a weighted average price of $5.15 per share. The highest sale price for the Common Stock was $5.16 per share and the lowest sale price was $5.15 per share. Read SEC document
October 15, 2019 Filed Oct 17, 2019 17:32 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	103,321	$4.98	$514,538.58	Disclosure SEC source: 0001103021-19-000021 · wf-form4_157134795109990.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,703,124 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · price: On October 15, 2019, the Reporting Person sold an aggregate of 103,321 shares of the Issuer's Common Stock at a weighted average price of $4.98 per share. The highest sale price for the Common Stock was $5.06 per share and the lowest sale price was $4.95 per share. Read SEC document
September 19, 2019 Filed Sep 19, 2019 17:02 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	24,506	$4.79	$117,383.74	Disclosure SEC source: 0001103021-19-000015 · wf-form4_156892691588929.xml · nonDerivative · entry 3 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,806,445 F3 · price: On September 19, 2019, the Reporting Person sold an aggregate of 24,506 shares of the Issuer's Common Stock at a weighted average price of $4.79 per share. The highest sale price for the Common Stock was $4.86 per share and the lowest sale price was $4.69 per share. Read SEC document
September 18, 2019 Filed Sep 19, 2019 17:02 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	43,686	$4.77	$208,382.22	Disclosure SEC source: 0001103021-19-000015 · wf-form4_156892691588929.xml · nonDerivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,830,951 F2 · price: On September 18, 2019, the Reporting Person sold an aggregate of 43,686 shares of the Issuer's Common Stock at a weighted average price of $4.77 per share. The highest sale price for the Common Stock was $4.81 per share and the lowest sale price was $4.73 per share. Read SEC document
September 17, 2019 Filed Sep 19, 2019 17:02 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	157,177	$4.79	$752,877.83	Disclosure SEC source: 0001103021-19-000015 · wf-form4_156892691588929.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,874,637 F1 · price: On September 17, 2019, the Reporting Person sold an aggregate of 157,177 shares of the Issuer's Common Stock at a weighted average price of $4.79 per share. The highest sale price for the Common Stock was $4.90 per share and the lowest sale price was $4.72 per share. Read SEC document
June 25, 2019 Filed Jun 27, 2019 18:00 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	90,706	$4.39	$398,199.34	Disclosure SEC source: 0000899243-19-018444 · doc4.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,031,714 Read SEC document
June 12, 2019 Filed Jun 13, 2019 18:00 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	177,495	$4.21	$747,253.95	Disclosure SEC source: 0000899243-19-016870 · doc4.xml · nonDerivative · entry 5 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,122,420 F1 · security: The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan. F2 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F4 · price: On June 12, 2019, the Reporting Person sold an aggregate of 177,495 shares of the Issuer's Common Stock at a weighted average price of $4.21 per share. The highest sale price for the Common Stock was $4.27 per share and the lowest sale price was $4.15 per share. Read SEC document
June 11, 2019 Filed Jun 13, 2019 18:00 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionOptions · Derivative	25,000	$0.00 Strike: $3.47	$0.00	Disclosure SEC source: 0000899243-19-016870 · doc4.xml · derivative · entry 8 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2021-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan. Read SEC document
June 11, 2019 Filed Jun 13, 2019 18:00 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionOptions · Derivative	22,369	$0.00 Strike: $3.55	$0.00	Disclosure SEC source: 0000899243-19-016870 · doc4.xml · derivative · entry 7 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,369 shares Expires 2021-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan. Read SEC document
June 11, 2019 Filed Jun 13, 2019 18:00 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionOptions · Derivative	37,348	$0.00 Strike: $3.90	$0.00	Disclosure SEC source: 0000899243-19-016870 · doc4.xml · derivative · entry 6 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,348 shares Expires 2020-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan. Read SEC document
June 11, 2019 Filed Jun 13, 2019 18:00 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	307,257	$4.22	$1,296,624.54	Disclosure SEC source: 0000899243-19-016870 · doc4.xml · nonDerivative · entry 4 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,299,915 F1 · security: The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan. F2 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F3 · price: On June 11, 2019, the Reporting Person sold an aggregate of 307,257 shares of the Issuer's Common Stock at a weighted average price of $4.22 per share. The highest sale price for the Common Stock was $4.42 per share and the lowest sale price was $4.15 per share. Read SEC document
June 11, 2019 Filed Jun 13, 2019 18:00 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionCommon Stock	25,000	$3.47	$86,750.00	Disclosure SEC source: 0000899243-19-016870 · doc4.xml · nonDerivative · entry 3 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,607,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 11, 2019 Filed Jun 13, 2019 18:00 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionCommon Stock	22,369	$3.55	$79,409.95	Disclosure SEC source: 0000899243-19-016870 · doc4.xml · nonDerivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,582,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 11, 2019 Filed Jun 13, 2019 18:00 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionCommon Stock	37,348	$3.90	$145,657.20	Disclosure SEC source: 0000899243-19-016870 · doc4.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,559,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 09, 2019 Filed May 10, 2019 18:03 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionRestricted Stock Units · Derivative	22,500	$0.00	$0.00	Disclosure SEC source: 0000899243-19-013106 · doc4.xml · derivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2020-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 of Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Quarterly Report for March 31, 2020. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 of Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Quarterly Report for March 31, 2020. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 of Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Quarterly Report for March 31, 2020. Read SEC document
May 09, 2019 Filed May 10, 2019 18:03 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionCommon Stock	22,500	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-013106 · doc4.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,522,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 22,500 of Restricted Stock Units ("RSUs") granted to the Reporting Person on April 17, 2019 under the Issuer's 2011 Equity Incentive Plan, as amended. The remainder of the RSUs under this grant will vest in the first open window upon the filing of the Company's Quarterly Report for March 31, 2020. Read SEC document
April 17, 2019 Filed Apr 19, 2019 18:01 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	GrantStock Options (Right to Buy) · Derivative	22,500	$0.00 Strike: $4.96	$0.00	Disclosure SEC source: 0000899243-19-010940 · doc4.xml · derivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-04-17 F2 · derivative.exercise_date: The stock options ("options") were issued to the Reporting Person on April 17, 2019, as compensation for service on the Issuer's board of directors. The options vest as follows: (i) 11,250 options vest in the first open window following the filing of the Company's Quarterly Report on Form 10-Q for quarter ended March 31, 2019, and (ii) 11,250 RSUs vest in the first open window following the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. The exercise price of the options is the volume-weighted average price of the Issuer's Common Stock for the 30-day period ending April 16, 2019. Read SEC document
April 17, 2019 Filed Apr 19, 2019 18:01 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	GrantRestricted Stock Units · Derivative	45,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-19-010940 · doc4.xml · derivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2020-05-09 F1 · derivative.exercise_date: The restricted stock units ("RSUs") were issued to the Reporting Person on April 17, 2019, as compensation for service on the Issuer's board of directors. The RSUs vest as follows: (i) 22,500 RSUs vest in the first open window following the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, and (ii) 22,500 RSUs vest in the first open window following the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. Read SEC document
March 21, 2019 Filed Mar 22, 2019 18:00 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	9,050	$5.20	$47,060.00	Disclosure SEC source: 0000899243-19-008813 · doc4.xml · nonDerivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,499,955 F3 · security: The shares of Common Stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F4 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth in these footnotes. F2 · price: On March 21, 2019, the Reporting Person sold an aggregate of 9,050 shares of the Common Stock at a weighted average price of $5.20 per share. The highest sale price for the Common Stock was $5.30 per share and the lowest sale price was $5.05 per share. Read SEC document
March 20, 2019 Filed Mar 22, 2019 18:00 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	GrantRestricted Stock Units · Derivative	19,463	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-19-008813 · doc4.xml · derivative · entry 3 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,463 shares Expires 2019-03-20 F1 · kind: The shares of Common Stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. F2 · derivative.exercise_date: On March 21, 2019, the Reporting Person sold an aggregate of 9,050 shares of the Common Stock at a weighted average price of $5.20 per share. The highest sale price for the Common Stock was $5.30 per share and the lowest sale price was $5.05 per share. Read SEC document
March 20, 2019 Filed Mar 22, 2019 18:00 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	GrantCommon Stock	19,463	$0.00	$0.00	Disclosure SEC source: 0000899243-19-008813 · doc4.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,509,005 F1 · price: The shares of Common Stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. Read SEC document
January 02, 2019 Filed Jan 4, 2019 18:02 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionOptions · Derivative	9,175	$0.00 Strike: $3.05	$0.00	Disclosure SEC source: 0000899243-19-000560 · doc4.xml · derivative · entry 3 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,175 shares Expires 2019-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan. Read SEC document
January 02, 2019 Filed Jan 4, 2019 18:02 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	9,175	$3.57	$32,754.75	Disclosure SEC source: 0000899243-19-000560 · doc4.xml · nonDerivative · entry 2 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,489,542 F1 · security: The shares of Common Stock were automatically exercised and sold under a pre-planned 10b5-1 trading plan. F2 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F3 · price: On January 2, 2019, the Reporting Person sold an aggregate of 9,175 shares of the Issuer's Common Stock at a weighted average price of $3.57 per share. The highest sale price for the Common Stock was $3.61 per share and the lowest sale price was $3.52 per share. Read SEC document
January 02, 2019 Filed Jan 4, 2019 18:02 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	Exercise / conversionCommon Stock	9,175	$3.05	$27,983.75	Disclosure SEC source: 0000899243-19-000560 · doc4.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,498,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 27, 2018 Filed Dec 28, 2018 18:07 UTC	BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876	SaleCommon Stock	10,000	$2.91	$29,100.00	Disclosure SEC source: 0000899243-18-031947 · doc4.xml · nonDerivative · entry 1 Sirgo Mark A · CIK 0001301715 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,489,542 F1 · security: The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan. F2 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F3 · price: On December 27, 2018, the Reporting Person sold an aggregate of 10,000 shares of the Issuer's Common Stock at a weighted average price of $2.91 per share. The highest sale price for the Common Stock was $3.02 per share and the lowest sale price was $2.86 per share. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.